Navigation Links
Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers
Date:6/14/2010

SUNNYVALE, Calif., June 14 /PRNewswire/ -- The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the Axxent® Electronic Brachytherapy, eBx™ System.  The leading provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides systems for single-dose intraoperative radiation therapy (IORT) and accelerated brachytherapy applications.  The most recent publication is four-year data from the TARGIT-A (Targeted Intraoperative Radiation Therapy) multicenter clinical trial presented this week at the 46th Annual ASCO Meeting and published in the current issue of the LANCET.

"We commend the TARGIT researchers and are encouraged that the study continues to reinforce the clinical value of isotope-free electronic treatment for IORT and accelerated brachytherapy applications," said Michael Klein, president and CEO of Xoft. "We are pleased with the growing adoption of IORT for breast and other cancers and we strongly believe that continued research will further prove its ability to improve patient care and similarly catalyze continued adoption."  

The TARGIT-A Trial is a randomized controlled trial designed to assess the equivalency of intraoperative radiotherapy with a single-dose against standard three to six week external beam radiotherapy after breast conserving surgery in women 45 years and over with invasive ductal carcinoma.

Results from the study, "Twelve-Month Follow-Up Results of a Trial Utilizing Xoft Axxent Electronic Brachytherapy to Deliver Intraoperative Radiation Therapy for the Early Stage Breast Cancer," were also presented recently at ASBS by Olga Ivanov, M.D., breast surgeon and medical director for Little Company of Mary's Comprehensive Breast Health Center.  The 12-month results suggest that IORT utilizing Xoft's Electronic Brachytherapy is emerging as a novel, patient and physician friendly alternative to Whole Radiation Therapy (WBRT) as well as APBI in a selected group of patients with early breast cancer.  At a mean follow-up of 12 months, overall results were encouraging with excellent scores achieved in cosmesis and patient satisfaction.  While long-term follow-up will continue, no recurrences have been observed to date.  

"I believe that giving a single fraction of radiation at the time of surgery is advantageous because it allows all the radiation to be delivered before any remaining tumor cells have a chance to grow and intensifies the dose to the part of the breast at highest risk for recurrence," said Adam Dickler, M.D., radiation oncologist at Little Company of Mary Hospital. "Additionally, by working in concert to deliver IORT treatment, breast surgeons and radiation oncologists may be better able to decrease the number of patients who decide to be treated with surgery alone despite the fact that radiation has been shown to be an essential component of treatment and increases overall survival."

IORT is a technique where a concentrated dose of radiation is delivered to a cancerous tumor site during surgery after the tumor is removed.  Because the target and normal tissues can be clearly identified during surgery, IORT may increase targeting accuracy, thereby increasing dose to the target and reducing dose to critical structures. For breast IORT, the shorter treatment time is generally more convenient for patients than the seven-week course of external beam-therapy, and may increase patient compliance.

Available for treatment of early stage breast cancer, endometrial cancer, and skin cancer, the Axxent System is also FDA-cleared for IORT and surface indications, which allows the system to be used on any external or internal surface of the body where radiation therapy is indicated.  As a platform technology, the System delivers non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.  In its treatment of early stage breast cancer, the Axxent System provides the opportunity to reduce the therapy time required from seven weeks (for external radiation therapy) down to five days or a single dose for IORT. Utilizing a miniaturized X-ray source instead of a radioactive isotope, the Axxent system can be used to deliver radiation in minimally shielded therapeutic settings allowing the radiation oncologist and other medical personnel to be present during treatment delivery which minimizes patient anxiety. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently.

About Xoft, Inc.

Xoft develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. The Axxent® treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the logistics and costs associated with using radioactive isotopes.  Available for treatment of early stage breast cancer, skin cancer and endometrial cancer, the Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. For information, visit www.xoftinc.com.

Axxent is a registered trademark and eBx is a trademark of Xoft, Inc.


'/>"/>
SOURCE Xoft, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):